Peptide & GLP-1 Growth Intelligence
A research brief for marketing clients selling peptides and GLP-1 medications: why demand exists, every channel the market uses to sell it (white-hat through grey), what each ad platform actually permits, and two complete 14-day execution roadmaps. Competitive intelligence only — nothing here is medical advice.
Scope note: this is a marketing and market-structure analysis prepared for client research. It documents how the peptide/GLP-1 market promotes and sells, including practices that operate in legal grey zones, so the client can make informed channel and compliance decisions. It is not medical advice, not legal advice, and not an endorsement of any tactic labeled risky or illegal on this page.
1 in 8
U.S. adults on a GLP-1 (KFF poll, 2026)
1.22M
Monthly U.S. searches: "tirzepatide"
$62.69
CPC for "semaglutide online"
50+
FDA warning letters to peptide sellers
Demand The market is mainstream now
- KFF: share of U.S. adults currently taking a GLP-1 climbed to 11% in 2026, up from ~3% two years earlier; roughly 1 in 8 adults ever-used. Half say the drugs are difficult to afford.
- UK: 4M+ NHS GLP-1 items dispensed in 2025/26, ~2.5M people/month buying privately, 3.3M UK adults expected to use in 2026 (YouGov/National Pharmacy Association).
- ~2M Americans source GLP-1s through online telehealth channels (Men's Health, 2025); the branded market alone is valued around $15B.
- Super Bowl advertising (Hims & Hers 2025, Serena Williams 2026) means the category now has full DTC pharma-style demand gen.
Enforcement The ground shifted in 2025–2026
- FDA issued 50+ warning letters across the peptide industry by September 2025; DOJ moved to criminal guilty pleas against grey-market distributors.
- Peptide Sciences — the largest U.S. grey-market research-peptide vendor (~$7.4M in December 2025 sales alone) — voluntarily shut down March 6, 2026 ahead of expected enforcement.
- FDA sent warning letters to Hims and other telehealth companies (Sept 2025) over "false or misleading" compounded GLP-1 advertising; a February 2026 FDA report flagged counterfeit Ozempic and "not for human consumption" workarounds.
- The SAFE Drugs Act (introduced 2026) targets the "research use only" loophole for compounds biologically identical to FDA-approved drugs.
Why People Search For and Use Peptides & GLP-1s
Demand is not one market. It is at least nine distinct jobs-to-be-done, each with its own searcher language, its own community, and its own sellable angle. The client's positioning should pick two or three of these deliberately — the buyers do not overlap as much as they look like they do.
| Demand driver | Who | Search language they use | Angle that sells into it |
|---|---|---|---|
| Weight loss / obesity Biggest | General public, mid-life, women skewing | ozempic, wegovy, zepbound, "how to get ozempic", "peptides for weight loss" (135K/mo) | Outcome story + access ("without insurance", "online prescription"), price transparency, eligibility quiz |
| Cost & access arbitrage Hottest | Uninsured / underinsured, price-shocked switchers | "semaglutide cost", "ozempic cost without insurance", "compounded semaglutide", "semaglutide online" | Price comparison, "$199/month all-in", coupon/savings angles, coverage-gap framing |
| Body recomposition & muscle retention | Biohackers, gym, men 25–45 | retatrutide ("reta"), "wolverine stack" (27K/mo), tirzepatide, IGF, "microdosing semaglutide" (4.4K/mo) | Protocol/stack content, "cut fat keep muscle", n=1 logs, community credibility |
| Longevity / anti-aging | Affluent biohackers, Attia-style audience | NAD+ injection (60.5K/mo), Epithalon, SS-31, glutathione | Science-forward content, optimization framing, premium bundles |
| Recovery & healing | Athletes, post-injury, older actives | BPC-157, TB-500, "wolverine stack" | Repair narratives ("gut lining, tissue repair"), stack bundles (BPC+TB-500) |
| Cognitive / mood | Knowledge workers, nootropics crowd | Semax, Selank, DSIP | "Clean focus" content, pairing guides (Semax + Selank) |
| Hair, skin & looks | Aesthetics buyers, women + hair-loss men | GHK-Cu, RU-58841, collagen peptides | Before/after aesthetics content, topical product lines |
| Libido & tanning | Looks-driven, younger | PT-141, Melanotan II, kisspeptin | Discreet direct-response, coded language |
| TRT & hormone management | Men's health clinics, existing TRT patients | enclomiphene, HCG, sermorelin (165K/mo), ipamorelin | Clinic bundles, "fertility-safe TRT", monthly membership |
How demand actually behaves (observed in the wild)
Pattern Education content is the top of every funnel
Cheat-sheet style content — compound lists grouped by job ("repair & recovery", "mass & power", "weight loss", "brain & sleep") with one-line plain-English descriptions and named stacks ("Wolverine", "GLOW", "KLOW", "CJC + Ipamorelin") — is the format that circulates. A peptides cheat sheet posted to r/Biohackers works precisely because it reads as a reference document, not an ad. Every comment thread on it turns into buyer behavior: first-timer anxiety ("how many units do I use?"), switching chatter ("started reta, considering NAD+"), and source hunting.
Pattern "DM me the source" is the market's native call-to-action
Across Reddit threads the recurring comments are "Can you DM sources?", "Any chance you can provide a source?", "DM source". Public channels can't show a storefront — so every platform conversation funnels into DMs, then WhatsApp/Telegram, then checkout. Vendors also seed proof in-thread: commenters name specific vendors alongside transformation stories ("dropped from 250 to 180 pounds... from [vendor]"). If the client wants community channels, the DM handoff is the conversion mechanism to design for — not a landing page click.
Intent tiers to build content around: cold ("tirzepatide side effects" — 110K/mo, "glp-1 for weight loss" — 40.5K/mo) → warm ("semaglutide cost", "microdosing semaglutide", "how to get ozempic" — 9.9K/mo at $34 CPC) → hot ("semaglutide online", "ozempic online prescription", "buy peptides online", "best peptide vendor"). Hot keywords are tiny in volume and enormous in value — they convert to $200+ orders. Cold keywords build the email list that converts them later.
Organic Selling Playbook (Exhaustive)
Organic is where this market actually lives, because paid platforms restrict the products. Every channel below is documented in active use. The creativity is in the framing, not the channel.
1. SEO: the money-page machine
| Page type | Example in the wild | Why it works |
|---|---|---|
| "Where to buy X" listicles | "Where to Buy Retatrutide Research Peptide in 2026" ranking on medical-sounding content networks (Plastic Surgery Key, Musculoskeletal Key) with ghostwritten procurement-writer bylines | Ranks for high-intent "where to buy / for sale" queries, launders vendor recommendations through an authoritative-looking masthead, and hands the reader to 1–2 "winning" vendors (often with affiliate relationships). The same article template is published across a network of niche medical sites. |
| Vendor comparison / "best X" pages | "Best Peptide Affiliate Program in 2026: 7 Programs Compared", "9 Peptide Vendors People Recommend, Ranked by How They Handle Quality" (LinkedIn article) | Comparison content captures shoppers mid-decision. Note vendors publish these about themselves, ranking competitors on criteria they win (COA transparency, payout terms). |
| Cost & savings pages | "semaglutide cost", "ozempic cost without insurance", "$X/month telehealth pricing" | The #1 warm-intent content type. Price transparency is the offer. |
| Protocol & explainer guides | Compound cheat sheets, stacking guides, dilution/mixing calculators, "how long does X take to work" | Definitive guides earn links from forums and get cited in Reddit threads — compounding authority. |
| Local / clinic pages | "peptide therapy near me" (9.9K/mo, LOW competition), "weight loss clinic near me" (40.5K/mo) | Local intent is winnable and cheap; medspa/clinic/telehealth hybrid plays dominate here. |
| Brand + review / reputation pages | "[vendor] review", "[clinic] reviews", "is [x] legit" | Absorbs the risk-research phase before purchase. |
2. Reddit: the demand-capture and seeding layer
Communities that matter
- r/Biohackers — cheat sheets, stacks, longevity protocols.
- r/Retatrutide and r/retatrutideUK — dedicated compound communities exist for the newest compounds before approval; UK regional spinoffs appear early.
- Adjacent: weight-loss, TRT, peptide therapy, longevity and fitness subs; clinician subs (e.g. r/FamilyMedicine) discussing the same compounds from the prescriber side.
Mechanics (both honest and grey)
- Value-first reference posts (the cheat-sheet format) that earn saves and comments.
- Comment answers to "where do I get..." questions; source-hunting comments are the highest-frequency intent signal on the platform.
- Vendor/affiliate mentions woven into transformation stories — the platform's version of seeded testimonials.
- Constraint to respect: subs auto-remove posts from new accounts (r/Biohackers blocks accounts under 15 days) and moderators remove spam aggressively — long-horizon accounts and genuine participation are the only durable play.
3. Quora & Q&A surfaces
- Question pages ("Where can I buy peptides?", "Is retatrutide safe?", "How much does semaglutide cost?") rank in Google and get read by buyers at the decision moment. Long, first-person, credential-flavored answers with soft links to guides are the standard structure.
- Q&A content is also reusable: the same answer distills into a Reddit comment, a TikTok script, and a newsletter section — one core story, many cuts.
4. Social: TikTok, Instagram, YouTube, and the DM funnel
Formats that circulate
- "Day in my life on GLP-1" / injection-day vlogs / transformation reveals with real, unpolished footage.
- Doctor and nurse explainers (white-coat authority); wellness coaches, beauty providers and influencers as spruikers — documented by researchers following the illicit Australian peptide market.
- Stack breakdowns and "compound tier list" videos — the video version of the cheat sheet.
The conversion mechanic
- Public bio/link is kept clean; the sale happens in comments → DMs → WhatsApp/Telegram catalogs with full price lists and photos.
- Documented flow: a targeted Instagram ad → WhatsApp greeting ("manufacturer supplying directly from the source, purity ≥99%, retail, small-batch, bulk, OEM") → per-vial price list → payment → discreet shipping. (The Conversation, July 2026.)
5. Newsletters, email & community assets
- Lead magnets: cheat sheets, dose-reference cards, cost calculators, "is GLP-1 right for you" quizzes — the list is the asset (emails convert a restricted-product buyer repeatedly).
- Sponsorships in biohacking, longevity, men's health and weight-loss journey newsletters — pharma-style audience buys where ads can't run.
- Telegram/Discord groups: protocol communities with vendor "verified" channels; group admins are effectively the affiliate layer.
6. Affiliate & creator armies (the real salesforce)
Observed program structures (from live vendor affiliate pages): commissions 10–20% (top tiers 25–30%), 30-day cookies, tier ladders by referred volume ($1K → 15%, $5K → 20%), 5% override on recruited sub-affiliates (unlimited team — a two-tier structure), payout by PayPal/Zelle/Venmo/Bitcoin, store credit uplift (+25%), no follower minimums ("new creators welcome" — BergdorfBio recruits explicitly on TikTok/Instagram), instant approval, ready-made social post templates. Average order values $200+ make a single referred sale worth $30+.
- Content rules vendors impose on affiliates are themselves a compliance map: no dosing/administration/before-after content, every post must state "for in-vitro laboratory research only", no trademark bidding. The rules exist because the brand needs the affiliate layer to launder what the brand can't say directly.
- Review and comparison sites ("7 programs compared", "9 vendors ranked") are frequently affiliate content wearing editorial clothing.
7. PR, earned media & newsjacking
- Expert commentary on every FDA announcement, shortage update, and celebrity story — news cycles around GLP-1s are constant.
- Editorial "best clinic" roundups in lifestyle/health magazines carry affiliate links ("We may earn a commission through links on our site" — Men's Health's own GLP-1 market guide is an example of the shoppable-guide format).
- Research partnerships and "we fund testing" stories (publishing COAs, sponsoring independent purity tests) build the trust narrative that this specific market obsesses over.
Creative angles that win (deconstructed)
"The system is broken"
Anti-establishment framing: "Obesity is America's deadliest epidemic. Something's broken — and it's not our bodies, it's the system." (Hims & Hers Super Bowl spot.) Sells access and defiance, not pharmacology.
The celebrity journey
Serena Williams' 2026 Super Bowl GLP-1 ad: first-person transformation normalization. Celebrity proof collapses buyer hesitation faster than any claim.
"Lab-grade" laundering
COAs, HPLC/LC-MS specs, named third-party labs, lot lookup libraries — research-grade aesthetics sell trust where medical claims can't be made.
The hidden-cause native hook
"87% of cases traced to one root cause", "Doctors are stunned", local-news chyron styling, unpolished phone photos, mechanism diagrams — native advertorial grammar.
Price transparency
"$199/month, medication + doctor + shipping" vs $1,000+ list price. The comparison is the ad.
Identity & tribe
"Biohacker" identity, protocol talk, stack names (Wolverine, GLOW, KLOW). Buyers join a movement that happens to have a shopping cart.
Paid Selling Playbook (Platform-by-Platform)
Short answer: yes, the big platforms restrict this category heavily — but not absolutely. Prescription drugs are advertisable on Meta and Google only by appropriately licensed/certified advertisers (LegitScript certification for telehealth/online pharmacies, plus platform authorization), with strict geo and age limits. Everything else in the market runs through workarounds, adjacent framing, or platforms with lighter moderation.
| Channel | Policy reality | What runs today | Risk |
|---|---|---|---|
| Meta (Facebook/Instagram) | Prescription drug ads allowed only for authorized advertisers: online pharmacies/telehealth must be LegitScript certified + Meta authorization, target only US/Canada/New Zealand, 18+ only. Weight-loss creative bans: fat-pinching close-ups, appearance-inferiority claims, clickbait, cure claims for listed diseases. Compounded-drug framing is enforcement-sensitive (FDA warned Hims et al. Sept 2025). | Big telehealth brands run compliant prescription ads after certification. Smaller players run: UGC/creator-whitelisted ads, "wellness program" framing (coaching + lifestyle, medication mentioned only on-site), lead-gen ads to eligibility quizzes, community/news-page identities. | High for anything drug-forward without certification |
| Google Ads & YouTube | Pharmacy/telehealth certification required for drug terms; GLP-1 landing pages get manual review (Ozempic-related queries especially). Brand-term CPCs are brutal: "semaglutide online" $62.69, "ozempic online prescription" $62.76, "tirzepatide" $28.57. | Certified telehealth bidding on brand + generic terms; competitor/conquest bidding; YouTube in-stream doctor explainers; "eligibility quiz" lead funnels; SEO landing pages fed by search ads. | Medium compliant; High if uncertified |
| TikTok | Weight-management ads restricted to 18+, healthy-lifestyle framing only; strong organic but strict ad moderation on claims. | Spark Ads whitelisting creator UGC; organic transformation content driving DM funnels; affiliate creators paid per sale rather than per impression. | Medium |
| Native: Taboola / Outbrain / MGID | Post-serve moderation (spot checks and sweeps) rather than pre-serve AI classification — structurally more permissive than Meta. | The advertorial workhorse: weight-loss and "metabolism support" / "blood sugar balance" reframed offers, joint-pain/longevity angles, fake-editorial masthead advertorials, before/after and fear hooks Meta would reject, mechanism-diagram creatives. Lower CPCs than Meta, weaker buyer intent, heavier landing-page friction. | Medium — sweeps and network bans happen |
| TV / CTV / streaming | Broadcast standards + FTC; pharma-style review processes. | Super Bowl (Hims 2025, Serena Williams 2026), CTV/OTT performance buys, direct-response infomercials for clinics and telehealth brands. | Lower if claims are defensible |
| Podcasts & radio | Sponsor-read norms; FTC endorsement rules apply. | Host-read ads on biohacking, longevity, men's health and comedy shows; promo codes for attribution. | Lower |
| Influencer / UGC (paid partnership) | FTC disclosure required; platforms restrict claims regardless of format. | Creator whitelisting is the #1 workaround for restricted categories — the ad account runs a person's story, not a brand's claim. UGC creators specialize in telehealth/weight-loss ("I make UGC ads for telehealth brands" is a live freelance category). | Medium |
| Direct mail / print / email drops | CAN-SPAM / postal rules; far looser than digital. | Weight-loss clinic postcards, magazine advertorials, solo email drops to purchased health lists. | Lower |
| Grey paid (what enforcement actually finds) | Violates platform policy and often law. | Ad-account farms and cloaked campaigns (policy-safe page to reviewers, sales page to users), click-to-WhatsApp ads selling from DMs, coded product names ("reta", "GLP-3"), crypto checkout, offshore entities. Documented in reporting on the illicit peptide trade. | Severe — account bans, payment-processor termination, FDA/DOJ exposure |
Where paid money actually goes in this category: (1) certified search ads on brand + cost keywords where CPCs justify $200+ AOV and subscription LTV; (2) native advertorials doing the education-heavy selling; (3) creator-whitelisted social; (4) podcast/newsletter sponsorships reaching audiences the platforms won't target. The unifying trick is moving the claim off the ad and onto a page, a person, or a publication.
The Advertorial Engine (How the Sell Is Structured)
Advertorials are the single most reused mechanism in this market — because they separate the risky claim (in editorial clothing) from the paid placement (which promotes "content"). Two flavors run simultaneously:
Paid flavor Native advertorial funnels
1 · Native ad
→
2 · Advertorial
→
3 · VSL
→
4 · Quiz
→
5 · Checkout
- Ad unit: unpolished human photo or labeled mechanism diagram + a precise-number or hidden-cause headline ("87% of cases traced to one root cause", "Doctors are stunned").
- Advertorial: fake publisher masthead + staff byline, "news discovery" framing, personal story lead, then mechanism explanation. The editorial frame does policy work: the network is promoting an article that makes no direct claim.
- Reframe language: "metabolism support", "blood sugar balance", "appetite management" instead of fat-loss promises — sidesteps platform classifiers and FTC weight-claim scrutiny.
- Close: VSL, eligibility quiz ("60-second assessment"), subscription checkout with monthly pricing.
Earned flavor Shoppable editorial guides
- Real publications run the same architecture with real editors: Men's Health's "Wild West of the Online GLP-1 Market" guide mixes narrative, safety journalism and affiliate-linked picks ("We may earn a commission").
- Medical-sounding content networks publish "where to buy" guides with ghostwriter bylines steering to chosen vendors — advertorial economics without an ad buy at all (pure SEO).
- Playbook to copy honestly: story-led lead with a real number, a document or reveal (COA, price list, trial data), a human outcome, then the offer. Add disclaimers and typical-results context — claims without substantiation are the FTC tripwire.
Grey Market Intel: How the Unregulated Side Operates
This section documents the market the client's competitors include — research-chemical vendors and offshore suppliers — so the client understands what they are competing against and where the enforcement line sits. Every item here is drawn from published reporting and observed vendor behavior, not speculation.
| Mechanism | How it works | What enforcement does about it |
|---|---|---|
| "Research use only" laundering | Compounds identical or adjacent to approved drugs (retatrutide, cagrilintide, BPC-157) sold as lab reagents with "not for human consumption" / "for in-vitro research only" disclaimers — while sites publish dosing guides, mixing calculators and transformation photos that make the human use obvious. | FDA's Feb 2026 report explicitly names the labeling workaround; the SAFE Drugs Act (2026) targets the loophole itself. Disclaimers don't create legal cover when marketing implies human use. |
| Overseas manufacturer direct | Chinese manufacturers advertise on Instagram, transact on WhatsApp: "supplying directly from the source, ≥99% purity, retail, small-batch, bulk, OEM orders", full price lists per vial, discreet shipping. Retail sites then dropship or resell domestically. | Import seizures, DOJ pleas against domestic distributors, payment-processor shutdowns. The manufacturer layer is hard to reach; the domestic reseller is the exposed link. |
| DM-commerce funnel | Public presence stays clean (memes, transformation content, "education"); the catalog, price list and payment link live in WhatsApp/Telegram/DMs. Coded terms ("reta", "GLP-3") and blurred product images survive moderation. | Platform enforcement is reactive — accounts get banned and reopen; researchers document the churn rather than its end. |
| Seeded social proof | Testimonials and vendor mentions planted in Reddit threads and reviews ("[vendor] took me from 250 to 180"); affiliate links inside "objective" comparison articles and "9 vendors ranked" posts. | FTC endorsement rules apply (undisclosed material connections); platforms remove vote-manipulated content when surfaced. |
| Two-tier affiliate MLM | 10–20% commissions plus 5% overrides on recruited sub-affiliates, instant approval, crypto payout options — the salesforce scales itself and disperses liability. | Affiliate terms shift risk to promoters ("no dosing, no before/after, must display research-only language") — which also documents the vendor's knowledge of intended use. |
| Trust theater | Public COA libraries searchable by lot number, named third-party labs (Janoshik, Vanguard, etc.), HPLC/LC-MS specs, "we publish where our data stops" honesty marketing. (Independent retesting still finds 15–20% of supplier COAs materially wrong — purity overstatement is the common failure.) | Not illegal per se — it's the market's trust layer. Legitimate brands should treat verified testing as the competitive baseline, not a gimmick. |
The enforcement scoreboard (2025–2026): 50+ FDA warning letters to the peptide industry · DOJ criminal guilty pleas against grey-market distributors · Peptide Sciences shut down March 2026 despite ~$7.4M monthly sales · FDA warning letters to Hims and other telehealth advertisers · counterfeits in the supply chain (1,000+ adverse-event reports tied to compounded GLP-1s as of the FDA's July 2024 count) · hospitalizations from illicit retatrutide reported in Australia. The message of this timeline: the grey market's ceiling got much lower between 2025 and 2026. Businesses built on the disclaimer loophole are now betting against active criminal enforcement, not just platform policy.
Rules & Risk Matrix
| Practice | FTC / FDA | Platform policy | Verdict |
|---|---|---|---|
| Prescription telehealth ads via LegitScript certification + authorization | Compliant if claims are substantiated and disclosures clear | Allowed (Meta US/CA/NZ 18+, Google certified) | Green — the big-boy path |
| Education content, price comparisons, quizzes, email capture | Compliant (no unproven claims) | Allowed | Green |
| Creator/UGC whitelisting, podcast/newsletter sponsorship | Disclosure required | Allowed with claim limits | Green with discipline |
| Native advertorials with reframe language ("metabolism support") | Grey — implied claims still need substantiation | Survives post-serve moderation, sweeps occur | Yellow |
| Compounded GLP-1 marketing (post-shortage landscape) | Warning letters already issued to telehealth advertisers | Case-by-case, tightening | Yellow — get counsel |
| "Research only" sales with implied human use | FDA explicitly targeting this (SAFE Drugs Act, Feb 2026 report) | Banned as drug sales | Red |
| Cloaked ads, account farms, fake mastheads making false claims, undisclosed affiliate seeding | FTC/FDA fraud exposure | Ban + merchant termination | Red — also criminal exposure |
14-Day Roadmap A: The Straight Path (“How the Big Boys Do It”)
Goal: a defensible, scaled acquisition engine — certified ads, SEO moat, content-led trust. Tags: AI = agent-executable, Both = AI + human, Manual = human-only (licenses, calls, legal).
Days 1–3 Foundation & compliance Manual
- 1. Claims matrix: every product/claim mapped to evidence (substantiation file). Cut anything unproven. Manual
- 2. Start LegitScript certification application + Meta/Google ad authorization requests — longest-lead item, start day 1. Manual
- 3. Positioning pick: choose 2–3 demand drivers from the map above (recommend: cost/access + weight loss; or recovery + longevity). Both
- 4. Offer architecture: monthly membership pricing with all-in transparency (medication + prescriber + shipping), guarantee policy, eligibility quiz spec. Both
Days 4–6 Site & funnel build Both
- 5. Ship the money pages: home, pricing, "how it works", eligibility quiz, FAQ/disclaimer hub. AI
- 6. Ship 5 SEO pages targeting warm intent: cost guide, "how to get [drug] without insurance", compound comparison, "X vs Y", "is [category] right for me". AI
- 7. Ship 2 local pages ("peptide therapy near me" play) if clinic/hybrid model. AI
- 8. Email capture live: lead magnet (cheat-sheet format — it's the format that circulates) + 5-email welcome sequence. AI
- 9. Tracking: conversions API, quiz funnel events, call tracking if applicable. Both
Days 7–10 Content & channel activation Both
- 10. Content engine, story-led: 1 flagship case/transformation story → 1 advertorial → 4–5 short video cuts → 1 newsletter issue. Real numbers as hooks, document/reveal structure. AI
- 11. Reddit presence: 2 value-first reference posts in target subs from an aged account, genuine comment participation. No links until earned. Both
- 12. Quora: 10 high-intent question answers distilled from the guides. AI
- 13. Creator recruitment: 15 micro-creators (TikTok/IG) on affiliate/whitelisting terms with disclosure templates. Both
- 14. Newsletter sponsorships booked in 2–3 biohacking/weight-loss lists. Manual
Days 11–14 Paid launch & iteration Both
- 15. Native advertorial test live (Taboola or Outbrain): 3 headlines × 2 creatives (unpolished photo + mechanism diagram), reframe language, quiz landing. Budget $2–4K test. Both
- 16. If certification approved: Meta search/lead ads + Google brand/cost keywords ("semaglutide cost", "ozempic cost without insurance"). Manual
- 17. Podcast host-read test (1 show, promo-code attribution). Manual
- 18. Review loop: kill/keep per creative, quiz completion rate, cost per qualified consult, email-to-consult rate. Both
Day-14 targets: site + quiz + email funnel live · 15+ indexable pages · 2 ad channels testing · 15 creators recruited · certification pipeline started (expect 2–6 weeks for approvals — organic and native carry growth until then). Economics to plan against: with $200+ AOV / $300+ first-90-day LTV and $25–60 blended lead costs in this niche, the straight path needs roughly 1-in-5 lead-to-consult and 1-in-2 consult-to-patient to clear CAC in month one — the quiz funnel is the lever on both numbers.
14-Day Roadmap B: The Grey Path (How It Actually Gets Done)
Read this as intelligence, not instruction. This is the operational shape of the grey market as documented in reporting and enforcement records. Each phase carries its real legal and platform exposure. A business executing this roadmap is betting against active FDA/DOJ enforcement that by 2026 includes criminal pleas and market-leader shutdowns. For most clients, the correct use of this section is: recognize these patterns in competitors, and stay several steps to the compliant side of them.
Days 1–3 Structure & supply Red zone
- 1. Supply: overseas manufacturer contact via Instagram/WhatsApp (documented flow: targeted ad → chat → price list → bulk/OEM). Domestic reseller or dropship front. Exposure: import seizures, distributor-level DOJ pleas.
- 2. Storefront: Shopify-style cart with coded product names ("reta", "GLP-3"), "research use only" sitewide language, COA page. Exposure: FDA explicitly targets this labeling pattern.
- 3. Payments: standard processors first, crypto option built in (affiliate payouts too). Exposure: processor termination, funds holds.
Days 4–7 Traffic & laundering Red zone
- 4. SEO listicles on medical-sounding content sites ("Where to Buy X in 2026", ghostwriter bylines) steering to the storefront. Exposure: FTC endorsement rules; deindexing.
- 5. Reddit/Telegram seeding: transformation testimonials naming the vendor, "DM source" harvesting, aged accounts (subs block new ones). Exposure: platform bans, community expulsion.
- 6. Social DM funnel: clean public bio, catalog in WhatsApp/Telegram, influencers/wellness coaches as the public face.
- 7. Paid: click-to-WhatsApp ads, cloaked campaigns and ad-account farms where direct ads are banned. Exposure: permanent asset loss (ad accounts, pixels, domains), and cloaking is the fact pattern platform enforcement treats as fraud.
Days 8–14 Scale & defend Red zone
- 8. Two-tier affiliate launch (10–20% + 5% sub-affiliate overrides, instant approval, crypto payouts) — the self-scaling salesforce.
- 9. Trust theater: publish COA library, sponsor independent purity testing, "ranked by quality" comparison content.
- 10. Continuity: rotate domains/accounts, backup processors, mirror stores. This is the churn researchers document — survival, not growth.
- 11. The exit math: the largest player in this exact model shut down voluntarily in March 2026 rather than face enforcement. Model the business on 12–24 month horizons, not 5 years.
What to steal from the grey market without the exposure: DM-first conversion design, community-native reference content (cheat sheets), price-transparency offers, COA/verification trust layers, affiliate army economics, and speed on new compounds (the market had retatrutide communities before approval). All of these are legal when the product, claims, and labeling are legal.
Keyword Battle Map (Measured, U.S., Google Ads Data)
Real search volumes and costs. Channel rule: SEO = winnable or too expensive to buy; Paid = high CPC but high intent — buy while building rank; Both = cheap clicks and winnable rankings.
| Keyword | Vol/mo | CPC | Ad comp | Best channel | Why / how to use it |
|---|---|---|---|---|---|
| tirzepatide | 1,220,000 | $28.57 | 100 | SEO | Biggest compound head term; definitive guide + comparison hub. Too expensive to own by ads. |
| zepbound | 823,000 | $24.65 | 78 | SEO | Brand awareness term; "Zepbound vs Mounjaro vs compounded" hub page. |
| mounjaro | 823,000 | $14.67 | 72 | SEO | Same hub strategy; cheapest of the big brand CPCs. |
| ozempic | 673,000 | $18.02 | 91 | SEO | Definitive "Ozempic in 2026" guide; feeds every warm page. |
| wegovy | 550,000 | $22.53 | 90 | SEO | Brand guide + cost/coverage content. |
| semaglutide | 368,000 | $33.65 | 99 | SEO | The generic money term; own the explanation layer. |
| sermorelin | 165,000 | $16.91 | 100 | Both | Peptide-category giant; clinic/telehealth offer page + guide. |
| peptides for weight loss | 135,000 | $9.54 | 100 | Both | Category-defining guide; cheap enough to buy while ranking. |
| tirzepatide side effects | 110,000 | $5.42 | 44 | SEO | Cold but huge; safety content captures researchers pre-purchase. |
| nad injection | 60,500 | $13.06 | 100 | Both | Longevity offer page + protocol guide. |
| glp-1 for weight loss | 40,500 | $33.22 | 100 | SEO | Pillar explainer; every internal link lands here. |
| weight loss clinic near me | 40,500 | $16.13 | 62 | Both | Local gold: pages + LSA/ads if clinic model. |
| compounded semaglutide | 33,100 | $29.77 | 100 | SEO | Regulatory-sensitive; honest guide with compliance disclaimers. |
| wolverine stack | 27,100 | $5.57 | 100 | Both | Stack-culture term growing fast (8K→49K in 12 mo); bundle pages. |
| peptide therapy | 18,100 | $7.51 | 59 | Both | Service landing page for clinics; affordable clicks. |
| peptide therapy near me | 9,900 | $6.94 | 24 | Both | Best gap on the board: real volume, LOW competition. Local pages win fast. |
| how to get ozempic | 9,900 | $34.37 | 100 | Both | Hot access intent; "access guide" → quiz funnel. |
| buy peptides online | 6,600 | $9.83 | 100 | Both | Pure buyer intent; vendor-comparison format. |
| ozempic cost without insurance | 5,400 | $13.88 | 81 | Both | Price-transparency page; converts to telehealth offers. |
| microdosing semaglutide | 4,400 | $27.10 | 100 | SEO | Trendy biohacker angle; protocol content. |
| semaglutide cost | 3,600 | $23.80 | 100 | Both | Cost calculator page + ad test. |
| semaglutide online | 3,600 | $62.69 | 100 | Paid | Smallest volume, highest intent — $200 AOV justifies buying. |
| ozempic online prescription | 880 | $62.76 | 99 | Paid | Bottom-funnel; buy the click, don't chase rank. |
| retatrutide / bpc-157 / ipamorelin / "best peptide vendor" / "buy semaglutide online" / "telehealth weight loss" | n/a* | — | — | SEO | *No Google Ads volume data returned — either too new, too restricted, or zero-AV. Retatrutide has entire Reddit communities and vendor pages despite zero ad data: proof that grey demand outruns the keyword tools. Build the pages early. |
Attack order: (1) "peptide therapy near me" + local pages — open field; (2) cost/access cluster — warmest intent per dollar; (3) compound pillar guides (tirzepatide/semaglutide/ozempic) — the authority moat; (4) stack-culture terms (wolverine stack, microdosing) — fastest growth; (5) retatrutide/next-compound pages — own them before the term matures.
Sources
| Topic | Source |
|---|---|
| U.S. adoption stats | KFF Health Tracking Poll — "1 in 8 Adults Say They Are Currently Taking a GLP-1" (kff.org) · FOX 35 Orlando poll summary (July 2026) |
| UK/market size | The Pharmaceutical Journal, "Everything you need to know about GLP-1s for weight loss" (July 2026) · National Pharmacy Association / YouGov poll (Jan 2026) |
| Online market & telehealth | Men's Health, "A Guide to Navigating the Wild West of the Online GLP-1 Market" (July 2025) · Infectious Disease Advisor / HealthDay telehealth dosing-errors report (June 2026) |
| Meta ad policy | Meta Transparency Center: "Drugs and Pharmaceuticals", "Health and Wellness" advertising policies |
| FDA enforcement | Endpoints News, "FDA calls out Hims and other telehealth companies for GLP-1 advertising" (Sept 2025) · The Conversation, "Ads for GLP-1 drugs are flooding the internet" (April 2026) |
| Grey market operations | The Conversation, "Where do peptides come from? We found out." (July 2026) · LinkedIn vendor-ranking articles (2026) · r/Biohackers peptides cheat sheet thread (Reddit) |
| Native/advertorial tactics | Daily Intel Service, "Native Ads for Nutra: Taboola and Outbrain Examples" (May 2026) · Taboola case studies · Zeely AI, "Weight loss advertisement: Examples & compliance" (Sept 2025) |
| Affiliate economics | True Peptides affiliate page · Validated Peptides, "Best Peptide Affiliate Program in 2026" · Evolve Peptides partner program · BergdorfBio affiliate program |
| Keyword data | Google Ads search volume data via DataForSEO (United States, English, pulled October 2026) |
Competitive research brief · for client strategy use only · not medical or legal advice